We assessed the in vitro antiviral activity of remdesivir and its parent nucleoside GS-441524,
molnupiravir and its parent nucleoside EIDD-1931 and the viral protease inhibitor …

Substantial progresshas been made in therapeutics for nonhospitalizedpatientswithCOVID-
19, butsupplyofand access to treatment remain limited. This Viewpoint summarizes currently …

Variants of SARS-CoV-2 have become a major public health concern due to increased
transmissibility, and escape from natural immunity, vaccine protection, and monoclonal …

Remdesivir is a nucleotide prodrug that is currently undergoing extensive clinical trials for
the treatment of COVID-19. The prodrug is metabolized to its active triphosphate form and …

The ongoing SARS‐CoV‐2 pandemic stresses the need for effective antiviral drugs that can
quickly be applied in order to reduce morbidity, mortality, and ideally viral transmission. By …

Abstract Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia with an unusual
outbreak in Wuhan, China, which is caused by severe acute respiratory syndrome …

Highlights•Remdesivir inhibits SARS-CoV-2 replication in Vero-E6 cells with EC 50 at 23.15
μM.•Lopinavir but not ritonavir inhibits SARS-CoV-2 replication with EC 50 at 26.63 μM.• …

Genetic variation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
resulted in the emergence and rapid spread of multiple variants throughout the pandemic, of …

Background Remdesivir has received significant attention for its potential application in the
treatment of COVID-19, caused by SARS-CoV-2. Remdesivir has already been tested for …

Although vaccination campaigns are currently being rolled out to prevent coronavirus
disease (COVID‐19), antivirals will remain an important adjunct to vaccination. Antivirals …